AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03589833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yisaipu
Description: Yisaipu, a Tumor Necrosis Factor Receptor Fusion Protein, was subcutaneously injected at a dose of 50 mg once a week for 24 weeks.
Study NCT04139291 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complex decongestive therapy phase 1
Description: Complex decongestive therapy-phase 1 program consist of meticulous skin and nail care, manuel lymphatic drainage, compression bandages, and remedial exercises. All patients will receive manual lymphatic drainage for three times a week (Monday-Wednesday-Friday) during 4 weeks, 50 minutes a day (a total of 12 sessions) by a trained lymphatic massage therapist.
Study NCT02929732 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sympathetic nervous activity measurement
Description: Polysomnography, MIBG myocardic scintigraphy, and 24h blood pressure measurement
Study NCT03045952 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: microwave ablation device
Description: Microwave ablation is a technique that uses thermal therapy to induce complete necrosis of tumor in situ by using microwave ablation device.
Study NCT04839640 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bredent denture teeth
Description: composite resin denture teeth
Study NCT04839640 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bredent denture teeth
Description: composite resin denture teeth
Study NCT03815344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard
Description: 20 units diluted in 100mL of Normal Saline injected laparoscopic needle
Study NCT03815344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard-vaginal misoprostol
Description: 20 units diluted in 100mL of Normal Saline injected laparoscopic needle and misoprostol 400 mcg
Study NCT03815344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard-vaginal misoprostol
Description: 20 units diluted in 100mL of Normal Saline injected laparoscopic needle and misoprostol 400 mcg
Study NCT02053155 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer based patient education
Study NCT04192708 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intercostal nerve block under direct vision
Description: When the intercostal nerve is adequated exposed，a surgeon use a 5ml syringe to perform the block and the needle is tilted 15 degree cephalad and advanced towards the caudal rim of the lib，and penetration depth is about 5mm.Then 1% lidocaine and 1/200000 epinephrine 3ml will be injected when negative aspiration of gas or blood.Same procedure will be repeted in the other two exposed intercostal spaces.
Study NCT04192708 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intercostal nerve block under ultrasound guidance
Description: After induction ，an ultrasonographic probe (M-Turbo with the L25 transducer; SonoSite Inc.) is used to scan laterally from the midaxillary line to identify the required anatomic landmarks, while the patients are in a lateral decubitus position. The ribs are identified as hyperechoic streaks, while the pleura appeared as hyperechoic lines between and below the ribs.The needle was advanced towards the caudal rim of the rib until the distal tip is just between the innermost and inner intercostal muscle.1% lidocaine and 1/200000 epinephrine 3ml will be injected when negative aspiration of gas or blood.Same procedure will be repeted in the other two exposed intercostal spaces.
Study NCT04192708 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: paravertebral block under ultrasound guidance
Description: Paravertebral block is performed between the thoracic segments T7-8,A linear ultrasound transducer (M-Turbo with the L25×transducer; SonoSite Inc.) is placed to parallel the T7 transverse process so as to identify the T7 spinous process，the T7 transverse process and 7th lib.Then move the probe caudally until the thoracic paravertebral space (TPVS) which is bounded by transverse process,pleura and internal intercostal membrane.Using in-plane technique, we advance the 20-gauge needle(Becton Dickinson Infusion Therapy Sysstems Inc.Sandy,Utah 84070,USA.1.88，1.1×48mm) until the needle tip penetrates the internal intercostal membrane,9ml mixture of 1% lidocaine and 1/200000 epinephrine after no blood or gas is aspirated.Both PVB and ultrasound-guided ICNB is performed by the same anesthesiologist
Study NCT04434183 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Exercises of rehabilitation
Description: Compare and evaluate of the effects of the routin physical medicine and rehabilitation programs in impingement patients
Study NCT01965847 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medication therapy management
Study NCT01965847 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication therapy management
Study NCT02009267 — intervention group
Intervention type: DEVICE
Intervention: Patient controlled analgesia
Description: A programable electronically controlled infusion pump that delivers an amount of intravenous analgesic when the patient presses a button.
Study NCT02009267 — intervention group
Intervention type: PROCEDURE
Intervention: Continuous thoracic epidural infusions
Description: Continuous thoracic epidural infusions (TE) involves continuous infusion of drugs through a catheter placed into the epidural space, resulting in a loss of sensation-including the sensation of pain-by blocking the transmission of signals through nerve fibers in or near the spinal cord.
Study NCT02009267 — intervention group
Intervention type: PROCEDURE
Intervention: Continuous paravertebral blockade
Description: Continuous paravertebral blockade (PVB) is the technique of injecting local anesthetic adjacent to the thoracic vertebra that anesthetizes the spinal nerve roots after they exit the spinal canal.
Study NCT01891955 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy diet A
Description: Healthy diet A will include fruit, vegetables, fish, shellfish, lean meat, nuts, eggs and olive oil. Macro/micronutrient composition, fiber intake and glycemic load will not differ from healthy diet B. Healthy diet A will include substantial amounts of whole grains, low-fat dairy and legumes (this is called healthy diet with grains and dairy). This diet is classified as very healthy using validated nutritional software. It is in accordance with official Spanish dietary recommendations for people with diabetes type 2 regarding macronutrient composition, dietary fiber, minerals and vitamins.
Study NCT01891955 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy diet B
Description: Healthy diet B will include fruit, vegetables, fish, shellfish, lean meat, nuts, eggs and olive oil. Macro/micronutrient composition, fiber intake and glycemic load will not differ from healthy diet A. Healthy diet B will exclude grains, legumes and dairy, which will largely be replaced by root vegetables, vegetables and fruit, and slightly more lean meat, fish and nuts (this is called healthy diet without grains and dairy). Salt intake will be lower in healthy diet B. This diet is classified as very healthy using validated nutritional software. It is in accordance with official Spanish dietary recommendations for people with diabetes type 2 regarding macronutrient composition, dietary fiber, minerals and vitamins.
Study NCT04704193 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey of Decision Aid
Description: The decision aid will be evaluated by a survey administered to those who have used the tool.
Study NCT01283984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2115
Description: Single dose, oral inhalation (nebuliser solution)
Study NCT01283984 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose, oral inhalation (nebuliser solution)
Study NCT00745134 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Optional correlative studies
Study NCT00745134 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological Study
Description: Optional correlative studies
Study NCT00745134 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Given PO
Study NCT00745134 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT00745134 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT00745134 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT00745134 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT03010852 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Focused incentive spirometer education and monitoring
Study NCT00705315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel as an IV infusion over 1h at the dose of 75mg/m2 every 3 weeks for 6 cycles
Study NCT00705315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubicin as an IV infusion over 10 min at the dose of 75mg/m2 every 3 weeks for 6 cycles
Study NCT00705315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab as an IV infusion over 1h at the dose of 15 mg/kg every 3 weeks for 6 cycles
Study NCT02402491 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 12 months of P2Y12 receptor antagonist
Description: All subjects will be received 12 months of dual antiplatelet therapy with a P2Y12 receptor antagonist (clopidogrel/prasugrel/ticagrelor) in addition to aspirin.
Study NCT02402491 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 24 months of P2Y12 receptor antagonist
Description: All subjects will be received 24 months of dual antiplatelet therapy with a P2Y12 receptor antagonist (clopidogrel/prasugrel/ticagrelor) in addition to aspirin.
Study NCT02402491 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin
Description: The maintenance dose of aspirin is 100 mg daily, to be taken indefinitely.
Study NCT02402491 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: The maintenance dose of aspirin is 100 mg daily, to be taken indefinitely.
Study NCT01121107 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Left Atrial Pressure Monitoring System
Description: Left atrial lead is placed for ambulatory monitoring of left atrial pressure
Study NCT01121107 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patient Advisory Module
Description: Handheld device that provides medication reminders
Study NCT01121107 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Patient Advisory Module
Description: Handheld device that provides medication reminders
Study NCT01242618 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: engineered nasal cartilage graft
Description: implantation of engineered nasal cartilage grafts in the alar lobule
Study NCT00825864 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: diclofenac drops
Description: one drop 4 times a day for 3 months
Study NCT00825864 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone sodium phosphate 0.1% eye drops
Description: for first week after the operation : one drop 6 times a day. Then tapering by reducing one drop for a week
Study NCT01836614 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: The treatment group will receive a 1.5mg/kg intravenous lidocaine bolus over 10 minutes after induction by means of an infusion pump. This bolus will be followed by an intravenous lidocaine infusion of 1 mg/kg/hr. The infusion will be stopped after extubation prior to leaving the operative room or after 5 hours from the start of the infusion, which ever comes first.
Study NCT01836614 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine
Description: The treatment group will receive a 1.5mg/kg intravenous lidocaine bolus over 10 minutes after induction by means of an infusion pump. This bolus will be followed by an intravenous lidocaine infusion of 1 mg/kg/hr. The infusion will be stopped after extubation prior to leaving the operative room or after 5 hours from the start of the infusion, which ever comes first.
Study NCT04500132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC-18
Description: EC-18 QD
Study NCT04500132 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo EC-18
Description: Placebo EC-18 QD
Study NCT00468871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluocinolone acetonide intravitreal implant
Description: surgical intravitreal implant of fluocinolone acetonide
Study NCT00468871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: corticosteroids and immunosuppressants
Description: Systemic corticosteroids alone or combined with immunosuppressants
Study NCT03489148 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tamarkoz®
Description: Tamarkoz® techniques includes six key elements: clearing the mind, breathing exercises, Movazeneh® (movement and balance exercises), deep relaxation, and visualization.
Study NCT03489148 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress management resources
Description: Use of the campus health center's stress management resources such as counseling, health-coaching, health and wellness groups, use of an automated massage chair, pet-an-animal a week, and online reading material about self-care for stress management.
Study NCT00085709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemtuzumab ozogamicin
Description: Given IV, induction Arm1 6mg/m2 D4; post-consolidation 5mg/m2 3 doses >/= 28 days apart
Study NCT00085709 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: observation
Description: No treatment given
Study NCT00085709 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytosine arabinoside
Description: IV; induction Arms1/2 and reinduction 100 mg/m2/d days 1-7; consolidation 3gm/m2 q3hrs D1, 3, 5
Study NCT00085709 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunomycin
Description: IV; induction Arm1 45mg/m2 D1-3; Arm2 and reinduction 60 mg/m2 D1-3;
Study NCT00004635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Thalidomide 200 mg given orally every evening at 9pm. Treatment may continue indefinitely provided that there are no dose-limiting toxicity.
Study NCT00004635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leuprolide acetate
Description: Injections of leuprolide once a month for six months.
Study NCT00004635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: goserelin
Description: Injections of Goserelin once a month for six months.
Study NCT01087177 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exposure to practice that has been trained in Pedialink CEASE
Description: Child has had an appointment at a practice that was trained in Pedialink CEASE at the time of the interview.
Study NCT04509713 — intervention group
Intervention type: BEHAVIORAL
Intervention: Collection of odour samples
Description: Samples of breath odours will be passively collected while participants wear the mask while breathing naturally, for at least 3 h. Skin odours will be passively collected by participants wearing the shirt and nylon socks for at least 12 h.
Study NCT00590603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic Trioxide, Ascorbic Acid and Bortezomib
Description: Phase I/Cohort I~Loading:~1. Arsenic Trioxide (ATO): 0.25 mg/kg IV over 1-2 hr qd x 5 days (Monday-Friday)~2. Ascorbic Acid: 1000 mg by IV infusion over 15 minutes after each infusion of arsenic trioxide qd x 5 days~Maintenance cycles (21 days)~1. ATO: 0.25 mg/kg IV over 1-2 hr once a week x 2 weeks every 3 weeks (one cycle) for a total of 6 cycles.~2. Ascorbic Acid 1000mg IV will be given within 30 minutes of completion of ATO.~3. Bortezomib 1 mg/m2 is administered intravenously in a 3-5 second bolus on days 1, 8 of a 21-day cycle. ATO is given at least one hour prior to Bortezomib. The first cycle will start on week 2, after loading dose week.~Phase I/Cohort 1 is followed by Cohort 2. Phase II uses maximum tolerated dose from Phase I.
Study NCT01346930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan
Description: 10 mg, tablet, once daily
Study NCT01724255 — intervention group
Intervention type: OTHER
Intervention: questionnaire
Study NCT03183232 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryosurgery or IRE surgery
Description: Cryosurgery or IRE surgery will be used in local tumor
Study NCT03183232 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: γδ T cell
Description: γδ T cells will be used against Lung Cancer
Study NCT03183232 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: γδ T cells/ A Cryosurgery or IRE
Description: Combination γδ T cell and Cryosurgery or IRE surgery will be used in Lung Cancer
Study NCT02703155 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Home Oral Glucose Tolerance Test kit
Description: Providing Home Oral glucose tolerance test kit to children with Cystic fibrosis for screening Cystic Fibrosis Related Diabetes
Study NCT00651378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: oral tablets: rosuvastatin 10 mg once daily for 6 weeks (switch from previous run-in with atorvastatin 10 mg daily)
Study NCT00651378 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe + Atorvastatin
Description: oral tablets: ezetimibe 10 mg plus atorvastatin 10 mg once daily for 6 weeks (add ezetimibe to previous run-in with atorvastatin 10 mg daily)
Study NCT00651378 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Double Atorvastatin
Description: oral tablets: atorvastatin 20 mg once daily for 6 weeks (double dose from previous run-in with atorvastatin 10 mg daily)
Study NCT01134419 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized handoff tool
Description: Informatics tool to aid in transfer of patient care information
Study NCT01134419 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Team training
Description: Teamwork training and revisions of handoff structure to optimize teamwork skills and verbal communications
Study NCT01134419 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Team training
Description: Teamwork training and revisions of handoff structure to optimize teamwork skills and verbal communications
Study NCT00422487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBX-2044
Description: MBX-2044 1.5 mg one capsule daily for 14 days
Study NCT02334332 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT00422487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBX-2044
Description: MBX-2044 4.5 mg three 1.5 mg capsules daily for 14 days
Study NCT00422487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBX-2044
Description: MBX-2044 15 mg one capsule daily for 14 days
Study NCT00422487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBX-2044
Description: MBX-2044 30 mg two 15 mg capsules daily for 14 days
Study NCT00422487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBX-2044
Description: MBX-2044 60 mg one capsule daily for 14 days
Study NCT00608907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: 1.3 mg/m\^3 on days 1, 4, 8, 11 over a 21-day treatment cycle
Study NCT00608907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib, rifampicin
Description: bortezomib 1.3 mg/m\^2 on days 1, 4, 8, 11 over a 21-day treatment cycle, rifampicin 600 mg once daily days 4 to 10 in cycle 3
Study NCT00608907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib, dexamethasone
Description: bortezomib 1.3 mg/m\^2 on days 1, 4, 8, 11 over a 21-day treatment cycle, dexamethasone 40 mg once daily days 1 to 4, and 9 to 12 in cycle 3
Study NCT04590794 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Soluble Urokinase Plasminogen Activator Receptor
Description: Participants will undergo sampling of peripheral venous blood, immediately after admission. Blood samples drawn from all patients and EDTA plasma will be stored at -80° C until later measurement. Plasma suPAR levels will be determined using the suPARnostic® ELISA assay (ViroGates, Denmark), which is based on a simplified double monoclonal antibody sandwich ELISA assay whereby samples and peroxidase-conjugated anti-suPAR are first mixed together and then incubated in anti-suPAR pre-coated micro wells. The recombinant suPAR standards of the kit are calibrated against healthy human blood donor samples. suPAR concentrations are determined as ng/mL plasma.
Study NCT03802786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imeglimin
Description: Single administration dose of imeglimin
Study NCT02971306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard medical therapy
Description: Standard medical therapy involves primary treatment with pentoxifylline at a dose of 400 mg three times a day and normal hospital nutrition (1800 to 2000 kcal per day). Diuretics, sodium restriction and albumin for treatment of ascites or fresh frozen plasma for coagulopathy or antibiotics for any focus of infection as spontaneous bacterial peritonitis (SBP), pneumonia, cellulitis, and urinary tract infection as indicated.